|
?:abstract
|
-
From the Document: To date, the U S Food and Drug Administration (FDA) has not approved any therapeutics--drugs or biologics--for the treatment of COVID-19 [coronavirus disease 2019] However, FDA has authorized the emergency use of three drugs, including two drugs that have been approved by FDA for other uses: hydroxychloroquine sulfate (\'hydroxychloroquine\') and chloroquine phosphate (\'chloroquine\') The agency authorized the emergency use of both drugs on March 28, 2020 [ ] Some stakeholders--including several former FDA officials--have expressed concern regarding FDA\'s EUA [emergency use authorization], stating that current data regarding the safety and effectiveness of these drugs for treatment of COVID-19 are largely anecdotal and that expanding access may jeopardize research into the drug On April 24, 2020, FDA issued a drug safety communication warning against the use of these drugs for treatment of COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems Further, the National Institutes of Health (NIH) treatment guidelines on use of antivirals for COVID-19 state that \'[t]here are insufficient clinical data to recommend either for or against using chloroquine or hydroxychloroquine for the treatment of COVID-19\' and recommend against using high-dose chloroquine for the treatment of COVID-19 COVID-19 (Disease);Therapeutics
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}